Boost your hair with FOL005

We have developed a derma cosmetic product, FOL005, for boosting hair and supporting healthy hair growth. Our objective is to launch it in the US, as the first market, in 2025 together with a commercial partner.

About FOL005

FOL005 is a peptide based product that has been tested on more than 300 persons with hairloss with potent effect on hair growth after only 4 months, with no side effects. It was initially a drug candidate project, hence it has been clinically tested and it has shown, in several studies, to be safe and tolerable. 

  • Clinically proven safety and efficacy
  • High responder rate (>70%)
  • For both men and women
  • Application only once daily

The market

The market for treatment of androgenetic alopecia (hair loss) is substantial. In the US alone 60 million men and 35 million women are suffering from hair loss whereas only 2,7 million men and 2 million women are being treated. The current market for medical treatments is valued at more than 8 billion USD globally (https://www.grandviewresearch.com/industry-analysis/alopecia-market).

Finasteride and minoxidil are the dominant medical treatments, which have limited effect and only up to 40% of patients respond to treatment. In the last 30 years no new medical treatment has been introduced and the pipeline is based mainly on reformulation of these existing therapies.

In the US alone 60 million men and 35 million women are suffering from hair loss whereas only 2,7 million men and 2 million women are being treated.

Milestones

2024: License agreement with commercial partners.

2024: Cosmetic tests carried out and necessary permits obtained in key markets.

2025: Production upscale finalized.

2025: Product launch in key markets.

Management

Jens Eriksson.

Jens Eriksson

Chairman of the Board

John Zibert.

John Zibert

CMO

Lars Rasmussen.

Lars Rasmussen

CFO

Jan Nilsson.

Jan Nilsson

Member of the Board